Effect of Sulindac Sulfide on Metallohydrolases in the Human Colon Cancer Cell Line HT-29
2011
Effects of Sulindac on Colon Cancer Cells
publication
Evidence: moderate
Author Information
Author(s): Hector Guillen-Ahlers, Jiangning Tan, Francis J. Castellino, Victoria A. Ploplis
Primary Institution: University of Notre Dame
Hypothesis
Does sulindac treatment affect metallohydrolases in human colon cancer cells?
Conclusion
Sulindac sulfide effectively downregulated MMP7 expression and activity in HT-29 human colon cancer cells.
Supporting Evidence
- Sulindac sulfide significantly increased cell death in HT-29 cells.
- MMP7 expression was downregulated by sulindac sulfide treatment.
- The study shows that sulindac's effects in mice may be relevant to human colon cancer.
Takeaway
Sulindac, a common anti-inflammatory drug, can help reduce a protein linked to colon cancer in human cells.
Methodology
HT-29 cells were treated with sulindac and its metabolites, and MMP7 expression was measured using RT-PCR and Western blotting.
Limitations
The study primarily focuses on a single cell line and may not fully represent in vivo conditions.
Statistical Information
P-Value
p=0.000001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website